<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35211632</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2328-8957</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Open forum infectious diseases</Title><ISOAbbreviation>Open Forum Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Circulation of Non-SARS-CoV-2 Respiratory Pathogens and Coinfection with SARS-CoV-2 Amid the COVID-19 Pandemic.</ArticleTitle><Pagination><StartPage>ofab618</StartPage><MedlinePgn>ofab618</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ofab618</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ofid/ofab618</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Our understanding of the cocirculation of infrequently targeted respiratory pathogens and their contribution to symptoms during the coronavirus disease 2019 (COVID-19) pandemic is currently limited. This research aims at (1) understanding the epidemiology of respiratory pathogens since the start of the pandemic, (2) assessing the contribution of non-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/influenza/respiratory syncytial virus (RSV) respiratory pathogens to symptoms, and (3) evaluating coinfection rates in SARS-CoV-2-positive patients, both vaccinated and unvaccinated.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Retrospective analysis of respiratory pathogens identified by the Johns Hopkins Diagnostic Laboratory between December 2019 and October 2021 was performed. In addition, we assessed the contribution of respiratory pathogens other than SARS-CoV-2 to symptomatic disease by retesting 2 cohorts of specimens that were (1) collected from symptomatic patients and (2) received limited respiratory pathogen testing. The first cohort was patients who tested negative by the standard-of-care SARS-CoV-2/influenza/RSV testing. The second was a cohort of SARS-CoV-2-positive, symptomatic, fully COVID-19 immunized and unimmunized patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Between December 2019 and October 2021, a total of 11 806, 62 829, and 579 666 specimens were tested for an extended respiratory panel, influenza/RSV with or without SARS-CoV-2 panel, or SARS-CoV-2, respectively. Positivity rates of different targets differed between different months and were impacted by the COVID-19 pandemic. The SARS-CoV-2-negative cohort had 8.5% positivity for other respiratory pathogens that included primarily enterovirus/rhinovirus (5.8%). In the SARS-CoV-2-positive cohort, no other respiratory pathogens were detected.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The COVID-19 pandemic impacted the circulation of certain respiratory pathogens. Other respiratory viral pathogens were associated with symptomatic infections; however, coinfections with SARS-CoV-2 were highly uncommon.</AbstractText><CopyrightInformation>© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Uhteg</LastName><ForeName>Katharine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Johns Hopkins Hospital Medical Microbiology Laboratory, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amadi</LastName><ForeName>Adannaya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Johns Hopkins School of Medicine, Division of Medical Microbiology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forman</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Johns Hopkins School of Medicine, Division of Medical Microbiology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mostafa</LastName><ForeName>Heba H</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Johns Hopkins School of Medicine, Division of Medical Microbiology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 DA045556</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HL143541</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 AI068613</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Open Forum Infect Dis</MedlineTA><NlmUniqueID>101637045</NlmUniqueID><ISSNLinking>2328-8957</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">coinfections</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>25</Day><Hour>5</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35211632</ArticleId><ArticleId IdType="pmc">PMC8863080</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofab618</ArticleId><ArticleId IdType="pii">ofab618</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Solomon DA, Sherman AC, Kanjilal S.. Influenza in the COVID-19 era. JAMA 2020; 324:1342–3.</Citation><ArticleIdList><ArticleId IdType="pubmed">32797145</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafa HH, Carroll KC, Hicken R, et al. . Multi-center evaluation of the cepheid Xpert (R) Xpress SARS-CoV-2/Flu/RSV test. J Clin Microbiol 2020. doi:10.1128/JCM.02955-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.02955-20</ArticleId><ArticleId IdType="pmc">PMC8106732</ArticleId><ArticleId IdType="pubmed">33298613</ArticleId></ArticleIdList></Reference><Reference><Citation>
Centers for Disease Control and Prevention.
Testing
 guidance for clinicians when SARS-CoV-2 and influenza viruses are co-circulating. Available at: https://www.cdc.gov/flu/professionals/diagnosis/testing-guidance-for-clinicians.htm. Accessed 7 February 2022.</Citation></Reference><Reference><Citation>Uyeki TM, Bernstein HH, Bradley JS, et al. . Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa. Clin Infect Dis 2018; 68:e1–47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6653685</ArticleId><ArticleId IdType="pubmed">30566567</ArticleId></ArticleIdList></Reference><Reference><Citation>
Centers for Disease Control and Prevention.
Overview of testing for SARS-CoV-2 (COVID-19). Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html. Accessed 7 February 2022.</Citation></Reference><Reference><Citation>
Centers for Disease Control and Prevention.
Multiplex assays authorized for simultaneous detection of influenza viruses and SARS-CoV-2 by FDA. Available at: https://www.cdc.gov/flu/professionals/diagnosis/table-flu-covid19-detection.html. Accessed 7 February 2022.</Citation></Reference><Reference><Citation>Mostafa HH, Carroll KC, Hicken R, et al. . Multicenter evaluation of the Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV test. J Clin Microbiol 2021; 59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8106732</ArticleId><ArticleId IdType="pubmed">33298613</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett J, Uhteg K, Forman MS, et al. . Clinical performance of the GenMark Dx ePlex respiratory pathogen panels for upper and lower respiratory tract infections. J Clin Virol 2021; 135:104737.</Citation><ArticleIdList><ArticleId IdType="pubmed">33497932</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris CP, Luo CH, Amadi A, et al. . An update on SARS-CoV-2 diversity in the United States national capital region: evolution of novel and variants of concern. Clin Infect Dis 2021. doi:10.1093/cid/ciab636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab636</ArticleId><ArticleId IdType="pmc">PMC8406876</ArticleId><ArticleId IdType="pubmed">34272947</ArticleId></ArticleIdList></Reference><Reference><Citation>Thielen PM, Wohl S, Mehoke T, et al. . Genomic diversity of SARS-CoV-2 during early introduction into the Baltimore-Washington metropolitan area. JCI Insight 2021; 6:e144350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8026189</ArticleId><ArticleId IdType="pubmed">33749660</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafa HH, Hardick J, Morehead E, Miller JA, Gaydos CA, Manabe YC.. Comparison of the analytical sensitivity of seven commonly used commercial SARS-CoV-2 automated molecular assays. J Clin Virol 2020; 130:104578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405824</ArticleId><ArticleId IdType="pubmed">32777761</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhteg K, Jarrett J, Richards M, et al. . Comparing the analytical performance of three SARS-CoV-2 molecular diagnostic assays. J Clin Virol 2020; 127:104384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194987</ArticleId><ArticleId IdType="pubmed">32361285</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaunt ER, Hardie A, Claas EC, Simmonds P, Templeton KE.. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J Clin Microbiol 2010; 48:2940–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2916580</ArticleId><ArticleId IdType="pubmed">20554810</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, Guo H, Zhou P, Shi Z-L.. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021; 19:141–54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization.
WHO health emergency dashboard. Available at: https://covid19.who.int/. Accessed 7 February 2022.</Citation></Reference><Reference><Citation>Huang QS, Wood T, Jelley L, et al. . Impact of the COVID-19 nonpharmaceutical interventions on influenza and other respiratory viral infections in New Zealand. Nat Commun 2021; 12:1001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7881137</ArticleId><ArticleId IdType="pubmed">33579926</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen SJ, Azziz-Baumgartner E, Budd AP, et al. . Decreased influenza activity during the COVID-19 pandemic-United States, Australia, Chile, and South Africa, 2020. Am J Transplant 2020; 20:3681–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7753605</ArticleId><ArticleId IdType="pubmed">33264506</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman AC, Babiker A, Sieben AJ, et al. . The effect of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) mitigation strategies on seasonal respiratory viruses: a tale of 2 large metropolitan centers in the United States. Clin Infect Dis 2021; 72:e154–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7717225</ArticleId><ArticleId IdType="pubmed">33161424</ArticleId></ArticleIdList></Reference><Reference><Citation>Uyeki TM, Wentworth DE, Jernigan DB.. Influenza activity in the US during the 2020-2021 season. JAMA 2021; 325:2247–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">34028492</ArticleId></ArticleIdList></Reference><Reference><Citation>Kevadiya BD, Machhi J, Herskovitz J, et al. . Diagnostics for SARS-CoV-2 infections. Nat Mater 2021; 20:593–605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8264308</ArticleId><ArticleId IdType="pubmed">33589798</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo CH, Morris CP, Sachithanandham J, et al. . Infection with the SARS-CoV-2 delta variant is associated with higher recovery of infectious virus compared to the alpha variant in both unvaccinated and vaccinated individuals. Clin Infect Dis 2021. doi:10.1093/cid/ciab986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab986</ArticleId><ArticleId IdType="pmc">PMC8903351</ArticleId><ArticleId IdType="pubmed">34922338</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall NC, Kariyawasam RM, Zelyas N, Kanji JN, Diggle MA.. Broad respiratory testing to identify SARS-CoV-2 viral co-circulation and inform diagnostic stewardship in the COVID-19 pandemic. Virol J 2021; 18:93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8087885</ArticleId><ArticleId IdType="pubmed">33933115</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang DD, Acree ME, Ridgway JP, et al. . Characterizing coinfection in children with COVID-19: a dual center retrospective analysis. Infect Control Hosp Epidemiol 2020; 1: 3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7545240</ArticleId><ArticleId IdType="pubmed">32962785</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowak MD, Sordillo EM, Gitman MR, Paniz Mondolfi AE.. Coinfection in SARS-CoV-2 infected patients: where are influenza virus and rhinovirus/enterovirus? J Med Virol 2020; 92:1699–700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267652</ArticleId><ArticleId IdType="pubmed">32352574</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafa HH, Fissel JA, Fanelli B, et al. . Metagenomic next-generation sequencing of nasopharyngeal specimens collected from confirmed and suspect COVID-19 patients. mBio 2020; 11:e01969–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7686804</ArticleId><ArticleId IdType="pubmed">33219095</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>